BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Serplulimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Serplulimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07283692-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07283692)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Neoadjuvant Serplulimab Plus Wee
 kly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/serplulimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07283692
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497530-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06497530)
DESCRIPTION:Serplulimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Mainten
 ance Lurbinectedin in Combination With Serplulimab for Patients With ES-SC
 LC\nEstimated primary completion: December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06497530
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06716619-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261219
DTEND;VALUE=DATE:20261220
SUMMARY:Serplulimab: Phase 1 readout est. (NCT06716619)
DESCRIPTION:Serplulimab\, phase 1.\nStudy: A Phase I Trial of Tumor-Associa
 ted Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors\nEsti
 mated primary completion: 19 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06716619
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05954429-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Serplulimab: Phase 2 readout est. (NCT05954429)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: A Study to Explore the Third-lin
 e Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-live
 r-limited Metastatic Colorectal Cancer: a Single-center\, Phase 2 Study\nE
 stimated primary completion: 28 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05954429
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06115642-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Serplulimab: Phase 1 readout est. (NCT06115642)
DESCRIPTION:Serplulimab\, phase 1.\nStudy: A Phase I Study to Evaluate the 
 Safety\, Tolerability\, and PK of HLX43 in Advanced/Metastatic Solid Tumor
 s\nEstimated primary completion: 30 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06115642
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05731726-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Serplulimab: Phase 2 readout est. (NCT05731726)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Serplulimab Combined With CAPEOX
  + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer\n
 Estimated primary completion: 30 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05731726
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433869-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06433869)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: The Efficacy of Bevacizumab and 
 Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rm
 hTNF-NC) in the Treatment of Malignant Ascites\nEstimated primary completi
 on: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /serplulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06433869
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439550-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06439550)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Adjuvant Treatm
 ent With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC\n
 Estimated primary completion: 31 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06439550
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391826-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07391826)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Megestrol Aceta
 te Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastro
 esophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serp
 lulimab Combined With SOX\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07391826
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05311189-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT05311189)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Study of HLX10\
 , Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Re
 current/Metastatic Gastric Cancer\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0531
 1189
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06280495-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Serplulimab: Phase 2/3 readout est. (NCT06280495)
DESCRIPTION:Serplulimab\, phase 2/3.\nStudy: Neoadjuvant Serplulimab & Beva
 cizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT\, pMMR/MSS CRC Patient
 s\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06280495
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06295926-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06295926)
DESCRIPTION:Serplulimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Serplul
 imab Combined With CCRT for LS-SCLC.\nEstimated primary completion: 25 Jan
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 295926
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257575-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07257575)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: A Randomized Co
 ntrolled Study of Serplulimab Combined With Chemotherapy for Locally Advan
 ced Gastric Adenocarcinoma\nEstimated primary completion: 31 January 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07257575
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446465-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Serplulimab: Phase 4 readout est. (NCT07446465)
DESCRIPTION:Serplulimab\, phase 4.\nStudy: FOLFOX Chemotherapy Combined Wit
 h Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initia
 lly Unresectable pMMR/MSS Colorectal Cancer\nEstimated primary completion:
  31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ser
 plulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07446465
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06601309-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06601309)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Biomarker Based Neoadjuvant Stra
 tegies for Locally Advanced Resectable ESCC\nEstimated primary completion:
  31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serpl
 ulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06601309
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101679-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07101679)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: A Study of GnP RegimenCombined W
 ith Serplulimab and Stereotactic Body Radiation Therapy as First-line Trea
 tment for Locally Advanced Pancreatic Cancer\nEstimated primary completion
 : 15 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serp
 lulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07101679
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583511-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07583511)
DESCRIPTION:Serplulimab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tenipos
 ide\, Cisplatin and Serplulimab for Treatment of ES-SCLC\, a Randomized Co
 ntrolled Study\nEstimated primary completion: 1 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07583511
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487519-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07487519)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Phase II Study of HLX43 Monother
 apy or Combined With Immune Checkpoint Inhibitors in Patients With Locally
  Advanced\, Recurrent\, or Metastatic Triple-negative Breast Cancer.\nEsti
 mated primary completion: 15 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07487519
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07403435-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07403435)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Short-course Radiotherapy Combin
 ed With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectab
 le ESCC\nEstimated primary completion: 31 May 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07403435
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253142-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07253142)
DESCRIPTION:Serplulimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab i
 n Subjects With Advanced Lung Cancer\nEstimated primary completion: 18 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07253
 142
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07457528-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07457528)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Efficacy and Safety of Neo-CRT P
 lus Serplulimab\, Nimotuzumab in Patients With Locally Advanced Resectable
  ESCC\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07457528
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06462105-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Serplulimab: Phase na readout est. (NCT06462105)
DESCRIPTION:Serplulimab\, phase na\, Small Cell Lung Cancer.\nStudy: Liposo
 mal Irinotecan Combination Regimen for First-line Treatment of Small Cell 
 Lung Cancer\nEstimated primary completion: 30 June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06462105
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128252-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Serplulimab: Phase na readout est. (NCT06128252)
DESCRIPTION:Serplulimab\, phase na\, Gastric Cancer.\nStudy: Clinical Study
  of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of
  Locally Advanced Gastric Cancer\nEstimated primary completion: 30 June 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06128252
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07506057-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07506057)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Trastuzumab in Combination With 
 Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unre
 sectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial
  Carcinoma After Failure of Standard Therapy\nEstimated primary completion
 : July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serpluli
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07506057
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07336953-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07336953)
DESCRIPTION:Serplulimab\, phase 3.\nStudy: A Phase III\, Randomized\, Clini
 cal Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Li
 ne Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (
 WGOG-PAN 006/ICSBR-2)\nEstimated primary completion: July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07336953
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358585-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Serplulimab: Phase 1/2 readout est. (NCT07358585)
DESCRIPTION:Serplulimab\, phase 1/2.\nStudy: A Phase Ib/II Study to Evaluat
 e HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Me
 tastatic Colorectal Cancer\nEstimated primary completion: 28 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07358585
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020247-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07020247)
DESCRIPTION:Serplulimab\, phase 3.\nStudy: Personalized Long-course Radioth
 erapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Stu
 dy\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07020247
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733050-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07733050)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Efficacy and Safety of Serplulim
 ab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-L
 ine Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma\n
 Estimated primary completion: 1 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07733050
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06531291-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06531291)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Surufatinib Com
 bined With Serplulimab and Standard Chemotherapy as First-line Treatment i
 n Advanced Solid Tumors With Neuroendocrine Differentiation\nEstimated pri
 mary completion: 9 August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/serplulimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06531291
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150949-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07150949)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Long-course Chemoradiotherapy or
  Short-course Radiotherapy Combined With CAPOX\, PD-1antibody\, and COX-2 
 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)\nEstimated prima
 ry completion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/serplulimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07150949
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07872696-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07872696)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Exploring the E
 fficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and
  SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Coho
 rt Study\nEstimated primary completion: September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07872696
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155122-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07155122)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Efficacy and Safety of Serplulim
 ab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited
 -Stage Small-Cell Carcinoma of the Esophageal\nEstimated primary completio
 n: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 serplulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07155122
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819604-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07819604)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Serplulimab Combined With CAPOX 
 and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Can
 cer\nEstimated primary completion: 1 September 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07819604
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604909-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270910
DTEND;VALUE=DATE:20270911
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07604909)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: A Phase II Randomized Trial of S
 erplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Color
 ectal Cancer After Adjuvant Chemotherapy\nEstimated primary completion: 10
  September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serp
 lulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07604909
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134218-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Serplulimab: Phase 2/3 readout est. (NCT07134218)
DESCRIPTION:Serplulimab\, phase 2/3.\nStudy: Neoadjuvant Chemoradiotherapy 
 Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Adva
 nced Rectal Cancer\nEstimated primary completion: October 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07134218
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898865-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07898865)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: NeoCSR-Omics Trial: CAPOX + Serp
 lulimab Before vs. After Short-course RT in LARC\nEstimated primary comple
 tion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /serplulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07898865
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05831891-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Serplulimab: Phase 2 readout est. (NCT05831891)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Fruquintinib Plus Serplulimab as
  First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma\nEs
 timated primary completion: 22 October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05831891
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340489-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07340489)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Serplulimab for Locally Advanced
  Cervical Cancer\nEstimated primary completion: 30 November 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07340489
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07347951-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07347951)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: A Single-center\, Phase II Study
  on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal
  Cancer\nEstimated primary completion: 1 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07347951
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622550-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07622550)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: A Single-arm\, Multicenter Clini
 cal Study of Fruquintinib Combined With Serplulimab and Chemotherapy as Fi
 rst-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal 
 Cance\nEstimated primary completion: 15 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07622550
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857279-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06857279)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: A Phase II Clinical Study to Eva
 luate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamou
 s Cell Carcinoma\nEstimated primary completion: 30 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06857279
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933471-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07933471)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Total Neoadjuva
 nt Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroe
 sophageal Junction Adenocarcinoma\nEstimated primary completion: 30 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0793
 3471
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Study of Precision Treatment for
  Rare Tumours in China Guided by PDO and NGS\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 erplulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06692491
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398937-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07398937)
DESCRIPTION:Serplulimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Com
 parison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resecta
 ble Stage II-IIIA Squamous NSCLC\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07398
 937
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06850103-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06850103)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: SCRT-CAPEOX-Serplulimab for MSS/
 pMMR Rectal Cancer With Oligometastases\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplu
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06850103
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07488533-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07488533)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Comparing the Combination of Sul
 lumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurren
 ce Risk Non Transparent Renal Cell Carcinoma\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 erplulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07488533
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07538180-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07538180)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Serplulimab\, Chidamide\, and Ri
 tuximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2
  Double-Expressor DLBCL\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07538180
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691632-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07691632)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Serplulimab Plus Decitabine and 
 CAPOX Before Surgery for Locally Advanced Colorectal Cancer\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/serplulimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07691632
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902648-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07902648)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Serplulimab\, DOS and Lenvatinib
  Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastri
 c/Gastroesophageal Junction Adenocarcinoma\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ser
 plulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07902648
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07943533-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07943533)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: HLX22 Combinati
 on Therapy in HER2-Positive Limited Metastatic Gastric Cancer\nEstimated p
 rimary completion: 31 December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07943533
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113275-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07113275)
DESCRIPTION:Serplulimab\, phase 3.\nStudy: A Clinical Trial Comparing Long-
 Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined
  With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed
  by TNT in Locally Advanced Rectal Cancer\nEstimated primary completion: 1
  January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplu
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07113275
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446049-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280109
DTEND;VALUE=DATE:20280110
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07446049)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: A Single-arm\, Open-label\, Mult
 icenter\, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With
  Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTE
 N Loss or Low Expression\nEstimated primary completion: 9 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07446049
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381400-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07381400)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Neoadjuvant mFOLFOX6 Chemotherap
 y Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Canc
 er (FIRM02 Study)\nEstimated primary completion: 1 February 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07381400
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466303-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07466303)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Serplulimab Combined With Trastu
 zumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer\n
 Estimated primary completion: 1 February 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07466303
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05742425-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Serplulimab: Phase 2 readout est. (NCT05742425)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Serplulimab Combined With FOLFIR
 I and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases\n
 Estimated primary completion: March 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05742425
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938021-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07938021)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: HLX22 Plus Serp
 lulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestina
 l Cancers\nEstimated primary completion: 1 March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07938021
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860529-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06860529)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Serplulimab Combined With Chemot
 herapy for Early-stage HR+/HER2- Breast Cancer\nEstimated primary completi
 on: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/se
 rplulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06860529
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621484-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07621484)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: HIPEC Priming F
 ollowed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer\n
 Estimated primary completion: 9 May 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07621484
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527520-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07527520)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Neoadjuvant Moderately Hypofract
 ionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High
 -risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective\, Multi-cente
 r Randomized Control Phase II Trial\nEstimated primary completion: July 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07527520
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134101-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07134101)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Neoadjuvant Therapy for Locally 
 Advanced Low Rectal Cancer (SMARTi-RC01)\nEstimated primary completion: 31
  August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplul
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07134101
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175389-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Serplulimab: Phase 1/2 readout est. (NCT07175389)
DESCRIPTION:Serplulimab\, phase 1/2.\nStudy: JDB153 Combined With Serplulim
 ab for Pancreatic Cancer After Standard Treatment Failure\nEstimated prima
 ry completion: 1 September 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/serplulimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07175389
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06580665-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Serplulimab: Phase na readout est. (NCT06580665)
DESCRIPTION:Serplulimab\, phase na\, Non-Small Cell Lung Cancer.\nStudy: Cr
 yoablation with or Without Serplulimab in Treating Patients with Stage I-I
 IA Non-small Cell Lung Cancer\nEstimated primary completion: 1 September 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06580665
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699939-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07699939)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Perioperative HLX10 (Serplulimab
 ) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastri
 c or Esophagogastric Junction Adenocarcinoma\nEstimated primary completion
 : 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 erplulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07699939
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231445-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Serplulimab: Phase 1 readout est. (NCT07231445)
DESCRIPTION:Serplulimab\, phase 1\, Small Cell Lung Cancer.\nStudy: Study o
 f ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as Fir
 st-Line Standard Therapy in Participants With Extensive Stage Small-Cell L
 ung Cancer\nEstimated primary completion: December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07231445
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277842-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07277842)
DESCRIPTION:Serplulimab\, phase 3.\nStudy: PD-1 + FOLFOXIRI vs CAPOX as Tot
 al Neoadjuvant Therapy for pMMR Low Rectal Cancer\nEstimated primary compl
 etion: 29 December 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/serplulimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07277842
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708285-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Serplulimab: Phase 1/2 readout est. (NCT07708285)
DESCRIPTION:Serplulimab\, phase 1/2.\nStudy: Luvometinib in Combination Wit
 h Serplulimab for NF2-Related Tumors\nEstimated primary completion: 31 Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7708285
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543848-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07543848)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: A Prospective\, Multicenter\, Si
 ngle-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic
  Virus H101\, Short-Course Radiotherapy\, and XELOX Chemotherapy as Total 
 Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer\nEsti
 mated primary completion: 31 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07543848
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07779694-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07779694)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: 16-Hour Fasting Plus Serplulimab
  and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal 
 Cancer\nEstimated primary completion: 31 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07779694
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854977-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07854977)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Fecal Microbiota Transplantation
  Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Adva
 nced or Metastatic Pancreatic Ductal Adenocarcinoma.\nEstimated primary co
 mpletion: May 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 erplulimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07854977
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739758-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07739758)
DESCRIPTION:Serplulimab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study
  of YL201 in Combination With Serplulimab in Participants With Treatment-n
 aïve Extensive-stage Small Cell Lung Cancer\nEstimated primary completion
 : June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serpluli
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07739758
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235930-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07235930)
DESCRIPTION:Serplulimab\, phase 3.\nStudy: Firstline Sequential AG and mFOL
 FOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone
  in Advanced Pancreatic Cancer\nEstimated primary completion: 1 July 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07235930
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507916-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07507916)
DESCRIPTION:Serplulimab\, phase 2\, Gastric Cancer.\nStudy: Dynamic ctDNA-G
 uided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal J
 unction Adenocarcinoma\nEstimated primary completion: 31 December 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07507916
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877597-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07877597)
DESCRIPTION:Serplulimab\, phase 3.\nStudy: Chemotherapy Combined With or Wi
 thout Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant T
 herapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS\nEstimate
 d primary completion: 31 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07877597
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854964-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300515
DTEND;VALUE=DATE:20300516
SUMMARY:Serplulimab: Phase na readout est. (NCT07854964)
DESCRIPTION:Serplulimab\, phase na.\nStudy: A Prospective\, Single-center\,
  Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in L
 ocally Advanced Rectal Cancer\nEstimated primary completion: 15 May 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07854964
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141771-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Serplulimab: Phase 1/2 readout est. (NCT07141771)
DESCRIPTION:Serplulimab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: An Um
 brella Study of Recurrent\, Extensive Stage Small Cell Lung Cancer Based o
 n Molecular Typing\nEstimated primary completion: 30 June 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07141771
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904156-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07904156)
DESCRIPTION:Serplulimab\, phase 3.\nStudy: A Phase III Randomized Controlle
 d Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk
  Non-Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 30 Dec
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7904156
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318883-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Serplulimab: Phase 2/3 readout est. (NCT07318883)
DESCRIPTION:Serplulimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplul
 imab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pe
 mbrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous 
 Non-Small Cell Lung Cancer\nEstimated primary completion: January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07318883
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772557-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07772557)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Adjuvant Therapy for Potentially
  Immunotherapy-Responsive Gastric or Gastroesophageal Junction Adenocarcin
 oma\nEstimated primary completion: 31 December 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/serplulimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07772557
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177443-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Serplulimab: Phase 3 readout est. (NCT07177443)
DESCRIPTION:Serplulimab\, phase 3.\nStudy: Serplulimab Combined With Induct
 ion Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma\nEstimated p
 rimary completion: 31 December 2035. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07177443
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07713745-2161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20360601
DTEND;VALUE=DATE:20360602
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07713745)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Platform Research for Innovative
  Medicines in NF2-SWN (PRIME-NF2)\nEstimated primary completion: 1 June 20
 36. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07713745
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
